474P - Effects of smoking habit in NSCLC with KRAS mutation in pathological stage I

Date 20 December 2015
Event ESMO Asia 2015 Congress
Session Poster presentation 2
Topics Non-Small Cell Lung Cancer
Aetiology, Epidemiology, Screening and Prevention
Translational Research
Basic Scientific Principles
Basic Principles in the Management and Treatment (of cancer)
Presenter Hiroaki Kuroda
Citation Annals of Oncology (2015) 26 (suppl_9): 125-147. 10.1093/annonc/mdv532
Authors H. Kuroda1, K. Seto2, T. Yoshida3, T. Mizuno3, N. Sakakura3, T. Hida3, Y. Yatabe4, Y. Sakao5
  • 1Thoracic Surgery, Aichi Cancer Center Hospital, 464-8681 - Nagoya/JP
  • 2Thoracic Surgery, Aichi Cancer Center Hospital, Nagoya/JP
  • 3Department Of Thoracic Oncology, Aichi Cancer Center Hospital, 464–8681 - Nagoya/JP
  • 4Department Of Pathology And Molecular Diagnosis, Aichi Cancer Center Hospital, 464-8681 - Nagoya/JP
  • 5Department Of Thracic Surgery, Aichi Cancer Center Hospital, Nagoya/JP



KRAS mutation plays important roles in the pathobiology of NSCLC and is well known to the resistance of EGFR inhibitors. KRAS mutation is strongly associated with smoking habit, but the non to light smoker having KRAS mutation rarely exist.


We conducted a retrospective study of 104 patients diagnosed as KRAS mutation compared to 217 patients with the diagnosis as Wild type in pathological stage I. The proportion of non to light smoker {smoking index (SI): 0 to 400} were 37.5 (39/104) in the patients with KRAS mutation.


KRAS with more than 400 in SI showed a shorter survival than KRAS with non to light smoker or Wild type (p = 0.03 and p < 0.01). The maximum tumor size and mediastinal size on preoperative CT was equivalent between the difference of smoking habit in KRAS mutation. Preoperative CEA was 4.56-fold higher in KRAS with more than 400 in SI than those with non to light (p < 0.01).


Our results suggested that KRAS mutation showed the poor prognosis in spite of stage I NSCLC. However, non to light smoker might have the possibility of contribution to improve prognosis among them.

Clinical trial identification


All authors have declared no conflicts of interest.